1,835
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Effect of nocturnal Temperature-controlled Laminar Airflow on the reduction of severe exacerbations in patients with severe allergic asthma: a meta-analysis

, , , , , , & show all
Article: 1894658 | Received 20 Oct 2020, Accepted 19 Feb 2021, Published online: 10 Mar 2021

References

  • Global Initiative for Asthma Global Strategy for Asthma Management and Prevention. 2018. http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention2018
  • Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
  • Hu J, Chen J, Ye L, et al. Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells. Clin Transl Allergy. 2018;8(1):27.
  • Lawrence MG, Steinke JW, Borish L. Cytokine-targeting biologics for allergic diseases. Ann Allergy Asthma Immunol. 2018;120(4):376–9.
  • Tice JA, Campbell JD, Synnott PG, et al. The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma. J Manag Care Spec Pharm. 2019;25(5):510–514.
  • Anderson WC III, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367–372.
  • Warner JO. Use of temperature-controlled laminar airflow in the management of atopic asthma: clinical evidence and experience. Ther Adv Respir Dis. 2017;11(4):181–188.
  • The National Institute for Health and Care Excellence (NICE). The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma. NICE MIBs. 2014;8:2014.
  • Boyle RJ, Pedroletti C, Wickman M, et al. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax. 2012;67(3):215–221. .
  • Bjermer L, Eriksson G, Radner F, et al. Time to onset of improvements in quality of life from temperature-controlled Laminar Airflow (TLA) in severe allergic asthma. Respir Med. 2019;147:19–25.
  • Schauer U, Bergmann KC, Gerstlauer M, et al. Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons. Eur Clin Respir J. 2015;2:2.
  • Pedroletti C, Millinger E, Dahlen B, et al. Clinical effects of purified air administered to the breathing zone in allergic asthma: a double-blind randomized cross-over trial. Respir Med. 2009;103(9):1313–1319.
  • Brazier P, Schauer U, Hamelmann E, et al. Economic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma. BMJ Open Respir Res. 2016;3(1):e000117.
  • SMPA. Behandlingsrekommendationer för astma hos vuxna och barn. 2015. (26-43) Available from: https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/Lakemedelsbehandling-vid-astma-behandlingsrekommendation-webb.pdf
  • Airsonett: Innovative Medical Technology Overview. Healthcare Improvement Scotland. 003/2015.
  • Kapoor M, Storrar W, Balls L, et al. Nocturnal temperature-controlled laminar airflow device for adults with severe allergic asthma: the LASER RCT. Health Technol Assess. 2019;23(29):1–140. .
  • Reddel HK, Taylor DR, Bateman ED, et al. An official American thoracic society/European respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99. .
  • Van Dijk BCP, Svedsater H, Heddini A, et al. Relationship between the asthma control test (ACT) and other outcomes: a targeted literature review. BMC Pulm Med. 2020;20(1):79.
  • Korn S, Both J, Jung M, et al. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011;107(6):474–479.
  • Del Giacco SR, Bakirtas A, Bel E, et al. Allergy in severe asthma. Allergy. 2017;72(2):207–220. .
  • Bateman ED, Buhl R, O’Byrne PM, et al. Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations. J Allergy Clin Immunol. 2015;135(6):1457–64 e4. .
  • Boer S, Sont JK, Loijmans RJB, et al. Development and validation of personalized prediction to estimate future risk of severe exacerbations and uncontrolled asthma in patients with asthma, using clinical parameters and early treatment response. J Allergy Clin Immunol Pract. 2019;7(1):175–82 e5.
  • Loymans RJB, Debray TPA, Honkoop PJ, et al. Exacerbations in adults with asthma: a systematic review and external validation of prediction models. J Allergy Clin Immunol Pract. 2018;6(6):1942–52 e15.
  • Blanco-Aparicio M, Vazquez I, Pita-Fernandez S, et al. Utility of brief questionnaires of health-related quality of life (Airways Questionnaire 20 and Clinical COPD Questionnaire) to predict exacerbations in patients with asthma and COPD. Health Qual Life Outcomes. 2013;11(1):85.
  • Van Boven FE, De Jong NW, Braunstahl GJ, et al. Effectiveness of the air purification strategies for the treatment of allergic asthma: a meta-analysis. Int Arch Allergy Immunol. 2020;181(5):395–402.
  • Spilak MP, Sigsgaard T, Takai H, et al. Comparison between temperature-controlled Laminar Airflow device and a room air-cleaner in reducing exposure to particles while asleep. PLoS One. 2016;11(11):e0166882.